Opinion

Video

Key End Points in Clinical Trials

Key Takeaways

  • Progression-free survival and overall survival are key endpoints in multiple myeloma trials, crucial for evaluating treatment efficacy.
  • Stringent eligibility criteria in clinical trials may limit their applicability to real-world scenarios, necessitating more inclusive designs.
SHOW MORE

Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
1 expert in this video
1 expert in this video
1 KOL is featured in this series.
1 expert in this video
1 expert in this video
Pharmacy Times OPC
5 experts in this video
1 expert is featured in this series.
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue.